Pharmaceuticals
Gracell Biotechnologies Announces Senior Management Team Share Purchase Plan
SUZHOU, China and PALO ALTO, Calif., Nov. 23, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, toda...
2021-11-23 22:00
3298
Neurophth Raised Over $60 Million USD in Series-C Financing to Advance Gene Therapies
SAN DIEGO, Nov. 23, 2021 /PRNewswire/ -- Neurophth Therapeutics Ltd., ("Neurophth"), a fully integrated genomic medicines company dedicated on seeking to improve lives through the curative potential of gene therapies, today announced the closing of over$60 million USD in Series-C financing with a...
2021-11-23 21:30
2589
Qilian International Holding Group Limited Announces Inclusion of Gan Di Xin® and Qilian Shan® Oxytetracycline into List for Development of Leading Enterprises with Large Varieties and Brands of Pharmaceuticals of Gansu Province
JIUQUAN, China, Nov. 23, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), aChina-based pharmaceutical and chemical products manufacturer, today announced that Gan Di Xin® and Qilian Shan® Oxytetracycline, products of the Company's subsidiary, Gansu Qi...
2021-11-23 20:00
2753
Bionomics Files Registration Statement for Proposed Initial Public Offering in the United States
ADELAIDE, Australia, Nov. 23, 2021 /PRNewswire/ -- Bionomics Limited (ASX:BNO, OTCQB:BNOEF) (Bionomics or Company), a clinical-stage biopharmaceutical company, today announced the public filing of a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the "SEC") in...
2021-11-23 19:37
4367
Simcere and Shanghai Institute of Materia Medica Enter a Collaboration to Jointly Develop Next-Gen COVID-19 Oral Antiviral Treatments
NANJING, China, Nov. 22, 2021 /PRNewswire/ -- On November 17, 2021, Simcere Pharmaceutical Group Limited (2096.HK) announced that the company has reached collaboration agreement with the Shanghai Institute ofMateria Medica (SIMM), Chinese Academy of Sciences (CAS), to develop novel antiviral drug...
2021-11-23 11:22
3118
Arctic Vision Announces First Patient Dosed in Phase III Study of ARVN001 for Treatment of Macular Edema Associated with Uveitis (UME)
* First-in-class SCS Microinjection therapy * First clinical registration study and potentially the first approved drug in China targeting macular edema associated with uveitis * U.S. FDA approved for treatment of macular edema associated with uveitis SHANGHAI, Nov. 22, 2021 /PRNewswire/ -- A...
2021-11-22 23:17
2200
Ascentage Pharma's Olverembatinib Granted Orphan Designation by the European Commission for the Treatment of Chronic Myeloid Leukemia
SUZHOU, China, and ROCKVILLE, MD., Nov. 22, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the European Commission (EC) has granted the...
2021-11-22 21:24
2514
Bispecific antibody drug against COVID-19 jointly developed by Shanghai ZJ Bio-Tech and Sanyou Biopharmaceuticals appearing at China International Import Expo (CIIE)
SHANGHAI, Nov. 22, 2021 /PRNewswire/ -- At the opening ceremony of the 4th China International Import Expo (CIIE) held inShanghai on November 6, 2021, SYZJ001, a bispecific antibody drug against COVID-19 jointly developed by Shanghai ZJ Bio-Tech Co., Ltd. and Sanyou Biopharmaceuticals (Shanghai) ...
2021-11-22 21:00
1970
TenNor Reports Positive Results of TNP-2092 Capsule for the Treatment of Liver Cirrhosis Hyperammonemia
SUZHOU, China, Nov. 22, 2021 /PRNewswire/ -- TenNor Therapeutics reports positive top-line results for TNP-2092 Capsule from a phase II clinical trial for the treatment of hyperammonemia/hepatic encephalopathy in patients with liver cirrhosis. TNP-2092 Capsule is an investigational new drug produ...
2021-11-22 21:00
1873
CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China
SUZHOU, China, Nov. 21, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, and Jiangsu Hengrui Pharmaceuticals ("Hengru...
2021-11-21 17:02
4417
Successful 2020 Tang Prize Award Ceremony Highlights Laureates' Achievements and Influence
TAIPEI, Nov. 20, 2021 /PRNewswire/ -- The 2020 Tang Prize Award Ceremony took place virtually at 2p.m. (GMT+8) onNovember 20. Eight 2020 recipients of the prize from seven countries, including the U.S., the U.K.,Japan, Singapore, Bangladesh, Colombia, and Lebanon, attended this heartwarming event...
2021-11-20 15:00
3597
Gracell Biotechnologies Granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy Candidate GC012F for the Treatment of Multiple Myeloma
SUZHOU and SHANGHAI, China, and PALO ALTO, Calif., Nov. 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today ...
2021-11-19 19:00
3078
111, Inc. Announces Third Quarter 2021 Unaudited Financial Results
SHANGHAI, Nov. 19, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the third quart...
2021-11-19 13:31
3772
ASRA 2021 | Cali Biosciences Presents Phase IIa Clinical Data on CPL-01, a Long-Acting Ropivacaine
SAN DIEGO, Nov. 19, 2021 /PRNewswire/ -- Cali Biosciences, a global biopharmaceutical company focused on the research and development of innovative drugs, presented Phase IIa clinical data today on its perioperative long-acting ropivacaine, CPL- 01, at the 20th Annual American Society of Regional...
2021-11-19 13:14
1839
China sees huge bounce in pharma rankings ahead of hybrid CPhI & P-MEC China
SHANGHAI, Nov. 18, 2021 /PRNewswire/ -- China's pharma industry has seen a record improvement in its overall score, growth potential and biologics according to new data. TheChina specific findings of the CPhI Annual Report rankings[1] are released ahead of CPhI & P-MEC China - which will take pla...
2021-11-18 15:00
1645
Inmagene files two international patent applications
SHANGHAI and SAN DIEGO and HANGZHOU, China, Nov. 17, 2021 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene" or the "Company") announced that it has filed two international patent applications for its drug candidates, IMG-007 (OX40 antagonist) and IMG-008 (IL-36R antagonist). One application...
2021-11-17 18:30
2165
Terumo Blood and Cell Technologies and Immunicom Establish Agreement to Launch Breakthrough Cancer Immunotherapy Treatment in Europe
* The therapy aims to re-energize a patient's immune system to fight cancer
tumors
* Initial commercialization will target leading oncology centers in Germany,
France, Italy, and Spain LAKEWOOD, Colo. and SAN DIEGO, Nov. 16, 2021
/PRNewswire/ --Terumo Blood and Cell Technologies
2021-11-17 00:00
2326
Senhwa Biosciences Announces Abstract Accepted for Presentation at the 2022 ASCO Gastrointestinal Cancers Symposium
TAIPEI and SAN DIEGO, Nov. 15, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that an abstract highlighting clinical design for their lead drug candidate...
2021-11-15 20:00
2392
Qilian International Holding Group Limited Announces Initiation of Development of New Drug for Gastric Cancer Prevention
JIUQUAN, China, Nov. 15, 2021 /PRNewswire/ -- Qilian International Holding
Group Limited (Nasdaq: QLI
2021-11-15 20:00
1884
Kintor Pharma Announces Dosing of First Patient in Phase II Clinical Trial of KX-826 for the Treatment of Androgenic Alopecia Female Patients in China
SUZHOU, China, Nov. 12, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the company has dosed the first patient in its phase II clinical ...
2021-11-12 14:17
2535
Week's Top Stories
Most Reposted
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 281 media titles]
2026-09-28 23:04
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 279 media titles]
2026-09-29 09:00
Allianz Partners unveils next-generation travel insurance platform to help partners navigate changing landscape
[Picked up by 269 media titles]
2026-09-28 07:30
Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 267 media titles]
2026-10-01 10:00
ViewSonic Launches VG1457 Dual-Screen Portable Monitor for Productivity Anywhere
[Picked up by 267 media titles]
2026-09-30 10:50
Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
23044
